Trial Profile
Phase II Trial of Atezolizumab (Anti-PD-L1) in the Treatment of Stage IIb-IV Mycosis Fungoides/Sezary Syndrome Patients Relapsed/Refractory After a Previous Systemic Treatment
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Cutaneous T-cell lymphoma; Mycosis fungoides; Sezary syndrome
- Focus Therapeutic Use
- Acronyms PARCT
- 21 Feb 2024 Status changed from active, no longer recruiting to discontinued.
- 26 Aug 2022 This trial have been completed in Germany and Greece (Date of the global end of the trial : 22-Aug-2022), according to European Clinical Trials Database record.
- 01 Oct 2021 Results (n=26; between 23rd October 2018 and 16th September 2019) assessing efficacy of atezolizumab in the treatment of stage IIb-IVB mycosis fungoides/Sezary syndrome patients relapsed/refractory after a previous systemic treatment, published in the European Journal of Cancer.